Fosamax Geriatric (65+) Monitoring: What Clinicians and Patients Need to Know

Why Geriatric Monitoring Differs From General Adult Care

Older adults on alendronate face a convergence of physiological changes that make standard adult monitoring protocols insufficient. Renal clearance declines at roughly 1 mL/min per year after age 40, GI motility slows, polypharmacy rates rise, and the skeleton itself may respond differently after prolonged bisphosphonate exposure. A 72-year-old with an estimated glomerular filtration rate (eGFR) of 38 mL/min who takes weekly alendronate sits within 3 mL/min of the FDA's hard contraindication threshold. That margin disappears with dehydration, a urinary tract infection, or a single course of NSAIDs.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 with 2,027 postmenopausal women, demonstrated a 47% relative risk reduction in radiographic vertebral fractures over three years with alendronate 5 mg/10 mg daily compared with placebo [1]. That evidence base is compelling, but FIT enrolled a relatively healthy population. Real-world geriatric patients often carry comorbidities, functional impairments, and drug burdens not represented in that cohort.

Structured monitoring exists to preserve the fracture-reduction benefit while detecting harm early enough to act on it. A monitoring framework built specifically around the geriatric patient is not optional; it is what separates competent prescribing from merely writing a refill.

Renal Function: The Non-Negotiable Parameter

Alendronate is renally excreted without hepatic metabolism, and its clearance drops sharply as kidney function declines. The FDA-approved labeling states that alendronate is not recommended for patients with creatinine clearance <35 mL/min [2]. In geriatric patients, serum creatinine alone is a poor surrogate for renal function because reduced muscle mass in older adults produces less creatinine, making the serum level appear deceptively normal. A 78-year-old woman weighing 52 kg with a serum creatinine of 1.1 mg/dL may have a Cockcroft-Gault CrCl of 32 mL/min. That calculation places her below the prescribing threshold.

Baseline and annual renal function assessments using CKD-EPI or Cockcroft-Gault are standard of care for older patients on alendronate. If eGFR falls below 35 mL/min on any re-check, the drug should be stopped and an alternative non-renally excreted agent such as denosumab or raloxifene discussed with the prescribing clinician.

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines for postmenopausal osteoporosis state that bisphosphonates should be used with caution and reassessment in patients with eGFR 35-60 mL/min and avoided below 35 mL/min [3]. That threshold applies with equal force in men receiving alendronate for glucocorticoid-induced osteoporosis or age-related bone loss.

Practical monitoring schedule for renal function:

• Baseline CMP or BMP including serum creatinine and calculated eGFR before starting therapy
• Repeat at 6 months after initiation
• Annual thereafter; more frequently if eGFR is 35-50 mL/min or the patient has a concurrent illness causing volume depletion

Bone Mineral Density Surveillance With DXA

Dual-energy X-ray absorptiometry (DXA) is the standard imaging modality for tracking skeletal response to alendronate. In geriatric patients, DXA monitoring answers two distinct questions: is the drug working, and is it time to consider a drug holiday or switch?

Alendronate produces the largest DXA gains in the lumbar spine, typically 5-8% above baseline over three years, and smaller but clinically meaningful gains at the femoral neck and total hip. A National Osteoporosis Foundation (NOF) position paper notes that a "significant" treatment response is generally defined as a gain or stability in BMD of more than the least significant change (LSC) for each DXA facility, which is usually 2-3% at the spine [4].

For a newly started geriatric patient, the recommended scanning interval is:

1. Baseline DXA before or at initiation
2. Repeat DXA at 1-2 years to confirm a treatment response
3. Every 2-3 years once BMD is stable

A meaningful decline in BMD despite documented adherence should prompt a medication review before assuming therapeutic failure. Common culprits include inadequate calcium and vitamin D intake, undiagnosed malabsorption (celiac disease has a prevalence of roughly 1% in older adults), poor adherence to the fasting and upright-posture dosing instructions, or a competing secondary cause of bone loss such as primary hyperparathyroidism.

If the T-score at the total hip rises above -2.5 and the patient has no history of prior fragility fracture after five years of treatment, guidelines from the American Society for Bone and Mineral Research (ASBMR) support considering a drug holiday of 2-3 years [5]. During the holiday, DXA every 2 years and prompt re-evaluation for any new fracture remain necessary. Patients with a hip T-score below -2.5 or a prior hip or vertebral fracture generally should not be placed on a holiday from alendronate.

Gastrointestinal Monitoring in Older Adults

GI tolerability is the most frequent reason older patients stop alendronate, and the consequences are direct: treatment gaps allow rapid bone loss to resume. Bisphosphonates bind to esophageal mucosa and cause local irritation, erosive esophagitis, and, rarely, esophageal ulceration. A 2017 analysis from the UK Clinical Practice Research Datalink found that oral bisphosphonate users had a statistically significantly elevated risk of esophageal adverse events compared with non-users, with the absolute risk concentrated in the first 90 days of therapy [6].

Geriatric-specific factors that increase GI risk include esophageal dysmotility, hiatal hernia, prior gastroesophageal reflux disease (GERD), reduced saliva production from anticholinergic drug burden, and difficulty maintaining the required 30-minute upright posture due to orthostatic hypotension or mobility limitations.

The HealthRX Geriatric Alendronate GI Risk Screen flags four conditions that warrant a clinician conversation before continuing weekly oral dosing:

1. Barrett's esophagus or active erosive esophagitis (relative contraindication; consider IV zoledronic acid instead)
2. Inability to sit or stand upright for at least 30 minutes after each dose
3. New-onset dysphagia or odynophagia within 30 days of starting therapy
4. Concurrent daily NSAID or aspirin use greater than 325 mg per day

Patients meeting any of these criteria should be reassessed within 4 weeks rather than waiting for the routine annual review. Upper endoscopy is appropriate when esophageal symptoms do not resolve within 2-4 weeks of dose interruption.

At each refill visit (typically every 3 months for a 90-day supply), asking two screening questions takes under one minute: "Any difficulty or pain swallowing?" and "Any heartburn that has worsened since your last visit?" A yes to either should generate a same-day telephone or portal follow-up.

Atypical Femur Fracture Surveillance

Atypical femur fractures (AFFs) are stress fractures of the subtrochanteric or femoral diaphysis associated with prolonged bisphosphonate use. They are rare, with an absolute risk of roughly 3.2-50 per 100,000 person-years depending on duration of use, but the relative risk rises steeply after five years of continuous therapy [7]. For context, the number needed to harm over ten years is estimated at approximately 2,000 patients, compared with a number needed to treat of roughly 50 to prevent one clinical fracture.

Older patients warrant specific attention because:

• Prodromal thigh or groin pain may be attributed to arthritis or musculoskeletal aging rather than an impending stress fracture
• Bilateral X-rays are often not obtained unless a clinician specifically orders them
• The fracture pattern (transverse with lateral cortical beaking) is distinctive but easy to miss on a plain film interpreted as a routine hip study

The ASBMR Task Force recommends obtaining bilateral femoral X-rays for any patient on bisphosphonates who reports new thigh, groin, or hip pain, even in the absence of trauma [5]. If an AFF is confirmed or suspected, alendronate should be stopped immediately and the patient referred to orthopedic surgery. Teriparatide has been studied as a potential agent to accelerate cortical healing after AFF, though the evidence base for that use remains limited.

Annual screening should include the direct question: "Have you had any new pain in your thighs, groin, or hips, even mild?" Document the response in the chart. If the answer is yes, do not wait; order bilateral femoral X-rays that week.

Calcium, Vitamin D, and Biochemical Markers

Alendronate will not work in a calcium- and vitamin D-deficient patient. The drug blocks osteoclast-mediated bone resorption, but bone formation still requires adequate substrate. Hypocalcemia is listed as a contraindication in FDA labeling, and subclinical vitamin D deficiency is remarkably common in geriatric populations, with some estimates placing prevalence above 40% in community-dwelling adults over 70 [8].

Before starting alendronate and at each annual visit, obtain:

• Serum 25-hydroxyvitamin D (25-OHD): target 30-50 ng/mL per the Endocrine Society's 2011 guidelines [9]
• Serum calcium and albumin (or ionized calcium if albumin is unreliable)
• Serum phosphorus if renal function is borderline

The standard supplementation recommendation for older adults on bisphosphonates is 1,000-1 to 200 mg of elemental calcium daily (dietary plus supplemental combined) and 800-1 to 000 IU of vitamin D3 daily, with higher doses (up to 2 to 000 IU/day) if baseline 25-OHD is below 20 ng/mL [3].

Bone turnover markers (BTMs), specifically serum C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP), can provide earlier evidence of alendronate's biochemical effect than DXA, sometimes as early as 3-6 months after initiation. The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry (IFCC) recommend P1NP as the reference marker for bone formation and CTX as the reference marker for resorption [10]. A CTX that fails to decline by at least 25-40% after six months of confirmed therapy should raise suspicion about adherence or absorption.

Drug-Drug Interactions in the Polypharmacy Context

Geriatric patients average five or more concurrent medications. Several common drug classes interact directly with alendronate's absorption or increase the risk of GI harm:

Calcium supplements: Taking calcium within 30-60 minutes of alendronate blocks absorption. Patients must take alendronate first thing in the morning, wait at least 30 minutes, then take calcium supplements if needed.

PPIs and H2 blockers: These reduce gastric acid and may slightly improve GI tolerance, but long-term PPI use is independently associated with reduced BMD and hip fracture risk in observational data. A 2012 meta-analysis in the Archives of Internal Medicine reported a pooled odds ratio of 1.30 (95% CI 1.18-1.43) for hip fracture among long-term PPI users [11]. Prescribers should document the indication for any PPI and reassess annually.

NSAIDs and low-dose aspirin: Both increase mucosal injury risk when combined with alendronate. If daily NSAID use is unavoidable, the risk-benefit of continuing oral bisphosphonate versus switching to intravenous zoledronic acid (5 mg once yearly) should be discussed.

Antacids containing aluminum, calcium, or magnesium: These bind alendronate in the GI tract and reduce absorption. They must not be taken within 30-60 minutes of the dose.

Glucocorticoids: Long-term glucocorticoid therapy accelerates bone loss and may itself be the indication for alendronate. Patients on prednisone 5 mg/day or more for three months or longer meet the American College of Rheumatology (ACR) threshold for bisphosphonate initiation, and monitoring intervals should be compressed to annual DXA at minimum [12].

A formal medication reconciliation at every visit, including over-the-counter supplements, is not a bureaucratic exercise. It is where the drug interaction that causes an esophageal ulcer or a missed AFF gets caught before it causes harm.

Falls, Fracture Risk Scoring, and Functional Assessment

Alendronate reduces fracture risk primarily by strengthening bone. It does not reduce fall frequency. In geriatric patients, 90% of hip fractures result from a fall, and falling is a behavior modifiable through exercise, medication review, and environmental intervention. A patient on alendronate who falls repeatedly is still at high fracture risk regardless of T-score improvement.

At baseline and annually, the following assessments integrate into the monitoring framework:

FRAX score: The WHO Fracture Risk Assessment Tool calculates 10-year probability of major osteoporotic fracture and hip fracture using age, sex, BMI, prior fracture history, parental hip fracture, smoking, alcohol, glucocorticoid use, rheumatoid arthritis, and femoral neck T-score. FRAX is available at shef.ac.uk/FRAX and does not require a DXA value if one is unavailable [13]. The National Osteoporosis Guideline Group (NOGG) and the NOF use FRAX thresholds to guide treatment initiation and continuation.

Timed Up and Go (TUG) test: A TUG time greater than 12 seconds in a geriatric patient is associated with elevated fall risk. This test takes under two minutes in clinic and requires no equipment beyond a chair and a stopwatch.

Medication review for fall risk: Benzodiazepines, anticholinergics, sedating antihistamines, and alpha-1 blockers all increase fall risk. Addressing polypharmacy-related fall risk may do more to reduce fracture incidence in a given patient than optimizing bisphosphonate dosing.

The Centers for Disease Control and Prevention (CDC) STEADI (Stopping Elderly Accidents, Deaths, and Injuries) toolkit provides standardized fall-risk screening instruments validated in primary care settings [14]. Annual STEADI screening is consistent with the monitoring framework for older adults on alendronate.

Deprescribing Alendronate: Thresholds and Process

Indefinite bisphosphonate use is not the goal. Alendronate accumulates in bone and continues to suppress resorption for years after discontinuation, a property known as the "bisphosphonate tail effect." This means a planned holiday can maintain fracture protection for a period after stopping. The FLEX (Fracture Intervention Trial Long-Term Extension) study followed FIT participants for an additional five years and found that women who continued alendronate beyond five years had lower rates of clinical vertebral fractures compared with those who switched to placebo, but no statistically significant difference in hip fracture rates was seen in the full population. A pre-specified subgroup with a femoral neck T-score below -2.5 at the five-year mark did show continued hip fracture benefit with ongoing therapy [15].

Based on FLEX and subsequent data, the ASBMR recommends the following approach after an initial 3-5-year treatment period:

• Low-to-moderate fracture risk (no prior hip or vertebral fracture, T-score above -2.5 at hip): Consider a drug holiday of 2-3 years. Resume if a new fracture occurs or if T-score declines below -2.5.
• High fracture risk (prior hip or vertebral fracture, or T-score at or below -2.5 at hip): Continue therapy or switch to an alternative agent with evidence in this subgroup.

During a drug holiday, the monitoring schedule does not stop. DXA every 2 years, annual fall-risk assessment, and prompt evaluation for any new pain or fracture should continue throughout the holiday period. Patients need explicit counseling that "stopping alendronate" is not the same as "stopping osteoporosis care."

The ASBMR Task Force report states: "Women who discontinue alendronate after 5 years of treatment retain significant anti-fracture protection for at least a year, but residual protection after 3 or more years off therapy is uncertain." [5]

Monitoring Adherence: The Overlooked Variable

Adherence to weekly oral alendronate in real-world geriatric populations is poor. A large claims-based analysis published in Osteoporosis International found that only about 40% of patients were still filling their alendronate prescription one year after initiation [16]. Non-adherence in bisphosphonate therapy correlates directly with higher fracture rates.

Barriers specific to older adults include:

• Complexity of the dosing regimen (fasting, upright posture, 30-minute wait, timing relative to other morning medications)
• Pill burden and cognitive load in patients managing 8-12 medications
• Side effects that resolve with correct technique but lead to discontinuation when technique is wrong
• Inadequate initial counseling at the time of prescribing

At each refill visit, direct questioning about technique is more productive than asking "are you taking your medication?" Ask specifically: "Walk me through how you take your alendronate on the day you take it." Patients who describe taking it with their morning coffee, or lying down after, require immediate re-education. Correct technique eliminates a substantial proportion of GI complaints attributed to the drug itself.

For patients with cognitive impairment or complex schedules, once-yearly intravenous zoledronic acid (Reclast, 5 mg infusion) removes the adherence variable entirely. The HORIZON Key Fracture Trial (N=7,765) demonstrated that IV zoledronic acid reduced vertebral fracture risk by 70% and hip fracture risk by 41% over three years in postmenopausal women [17], and a landmark sub-study found a 28% reduction in all-cause mortality after hip fracture repair. IV administration guarantees complete drug delivery and is appropriate to discuss with any geriatric patient struggling with the oral regimen.

Summary Monitoring Schedule by Domain

For a geriatric patient on alendronate 70 mg once weekly, the following monitoring schedule integrates all domains discussed above:

Before starting: Serum creatinine with calculated eGFR, 25-OHD, serum calcium, baseline DXA (spine and hip), FRAX score, falls assessment, full medication reconciliation, esophageal contraindication screen.

At 3-6 months: Symptom review (GI tolerability, new thigh or groin pain), 25-OHD recheck if baseline was deficient, serum CTX or P1NP to confirm biochemical response.

Annual: Serum creatinine/eGFR, serum calcium, 25-OHD, falls assessment (TUG or STEADI), direct inquiry about thigh/groin/hip pain, medication reconciliation, adherence technique review, FRAX recalculation if major clinical change.

Every 1-2 years initially, then every 2-3 years: DXA (spine and total hip). More frequent scanning if new fracture, significant steroid exposure, or decision about drug holiday is pending.

At 3-5 years: Formal risk reassessment for drug holiday versus continuation using current T-score, fracture history, and FRAX score.